alt

XIX International AIDS Conference (AIDS 2012)

July 2012, Washington, DC

AIDS 2012: HIV+ Men Prone to Bone Fractures at Earlier Age

HIV positive men in the long-running MACS cohort appeared to sustain osteoporosis-related bone fractures at an earlier age than HIV negative men, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC. A related study found several factors that predict greater risk of fractures, including use of protease inhibitors and proton pump inhibitors. alt

Read more:

AIDS 2012: Quad Matches Atripla and Atazanavir Regardless of Viral Load or CD4 Count

The 4-in-1 Quad pill containing the next-generation integrase inhibitor elvitegravir worked as well as both the Atripla coformulation and the boosted protease inhibitor atazanavir (Reyataz) for people with either high or low baseline viral load and CD4 T-cell counts, according to 2 poster presentations at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.alt

Read more:

AIDS 2012: Rapid Liver Disease in HIV+ Men with Acute HCV: The Debate Continues

Gay and bisexual men who are already HIV positive when they become infected with hepatitis C virus (HCV) may experience unusually rapid and severe liver disease progression, according to a presentation by Daniel Fierer at the XIX International AIDS Conference (AIDS 2012) last month in Washington, DC. Other experts, however, disagree with this conclusion.

alt

Read more:

AIDS 2012: HIV Viral Load Trends in San Francisco, 2001-2011

More potent antiretroviral regimens and a policy of offering treatment to everyone who tests HIV positive regardless of CD4 T-cell count has led to widespread viral suppression and a declining "community viral load" in San Francisco, researchers reported at the XIX International AIDS Conference (AIDS 2012) last month in Washington, DC.

alt

Read more:

AIDS 2012: New Antiretrovirals Formulations for Children Are Promising, More Still Needed

Promising new formulations of antiretroviral agents including tenofovir and fosamprevanir for treating the often neglected needs of infants and children with HIV were presented in an oral abstract session at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC. Related presentations covered new treatments for HIV positive adolescents.alt

Read more: